Data needs to be a foundation for evidence-based action.
Real-time data collection and analysis played a vital role in shaping policy decisions during the pandemic, setting a precedent for strategies to effective cancer control;
Innovations need to be disruptive to transform cancer care.
The pandemic revealed the urgency for modernizing cancer care processes and embracing innovation that changes the status quo;
Social determinants of health matter more than ever before.
Tackling inequities is crucial for alleviating the disproportionate burden of cancer on marginalized communities.
Prevention is the best defence.
The importance of prevention was underscored during the pandemic, emphasizing its role in improving health outcomes and reducing costs.
Like COVID-19, cancer requires a collective commitment from governments, regulators, payors, healthcare providers, patients and patient groups, communities, and stakeholders, such as the pharmaceutical, biotech and technology industries. The goal needs to be allocating resources, fostering innovation, and re-evaluating our healthcare priorities — together.
Political will is also important. Prioritizing cancer care demands a commitment from our leaders, and as we navigate the aftermath of COVID-19, it’s imperative that we channel the same sense of urgency, collaboration, and innovation into the cancer fight and bring it to the forefront of the national agenda.
